{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.2","upperLimit":"4.3","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"Measured from date of registration to date of first observation of progressive disease or death due to any cause. Patients last known to be alive and without report of progressive disease are censored at date of last contact. Progressive disease is at least 50% increase in the sum of the product of the diameters (SPD) of target measurable nodal lesions over the smallest sum observed or ≥ 50% increase in the greatest transverse diameter (GTD) of any node \\> 1 cm in shortest axis, or ≥ 50% increase in the SPD of other target measurable lesions over the smallest sum observed. New bone marrow involvement. New lesion \\> 1.5 cm in longest axis, or ≥ 50% increase in GTD of any previously involved node with a diameter ≤ 1.0 cm in the short axis such that its longest axis is now \\> 1.5 cm. Lymph nodes with long axis is \\> 1.5 cm, or if the both the long and short axes are \\> 1 cm. PET should be positive if positive PET at baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive MLN8237 (alisertib) PO BID on days 1-7. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity","id":"OG000","title":"MLN8237"}],"paramType":"MEAN","populationDescription":"Only eligible patients were included in the analysis","reportingStatus":"POSTED","timeFrame":"Up to 2 years after registration","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}